Most Read on APEsphere
Most Commented on APEsphere
Blogs we like
Resources
Having spent a few years as a compliance professional in the financial sector, I was intrigued to read about the detail of the Pfizer settlement.
The drug company Pfizer, you'll recall, has just settled with the US Department of Justice for a total financial penalty of $2.3 billion - the largest ever. The allegations against Pfizer concerned illegal marketing of painkiller Bextra and several other drugs.
What did not come through in the original reports was that in one part of the settlement, the inspector general of the US Department of Health and Human Services (HHS) required Pfizer to change the reporting line of the company's compliance department from the General Counsel to the Chief Executive.
In-house compliance professionals are often in a bit of a bind. They are supposed to advise the business on how it needs to conduct itself if it is to remain within the letter of the regulations. Their reporting line, however, is often to someone with a strong personal interest in the short-term financial success of the business development to which the advice relates. Although compliance departments inevitably attract the label of "business prevention", their reporting lines (and remuneration and retention prospects) in fact incentivise them to bend over backward to accommodate the concerns of their superior. So much for independence.
In Pfizer's case compliance reported to the general counsel. As Lewis Morris, general counsel for the inspector-general's office put it:
"The lawyers tell you whether you can do something, and compliance tells you whether you should ... We think upper management should hear both arguments."
If that is what the lawyers are there to do, then they will be rewarded on the basis of their overall contribution to business development. Compliance reporting into that setup risk ending up singing the same tune, or leaving.
I predict regulators will become more prescriptive about the precise reporting lines of compliance professionals. I am not sure, though, that instituting a reporting line to the chief executive is the most effective course though. Although the CEO has a group-wide interest and won't want the actions of a particular division to threaten the overall reputation of the group, the CEO is still guided by short-term financial incentives. A better solution might be a reporting line into the audit committee of the board, which should be majority comprised of independent non-executives.
An investigative report by Francine McKenna at re:The Auditors raises conflict of interest questions about PwC's IT implementation business.
Auditor independence is essential to audit work, but some of the Big 4 audit firms - or at least some of their partners - are not happy with their cosy oligopoly and want a piece of the more lucrative consulting and big project (especially IT) implementation market. That might be fine if they were not offering consultancy to clients they were also auditing, or auditing clients that they hoped to get consultancy work from.
Satyam, the Indian IT outsourcing company, housed one of the biggest accounting frauds discovered over the last year, and PwC was the auditor. In the report Francine reviews what appears to have been a strategic relationship between PwC and Satyam for the delivery of IT implementation services to PwC's IT consultancy clients.
Time to clamp down again on auditor independence?
The US National Institutes of Health (NIH) is consulting on whether to tighten rules relating to conflicts of interest in medical research it finances.
The move comes following growing concern about the objectivity of research that has been financed or materially supported by drug companies or medical device manuafacturers.
The Institute of Medicine, part of the influential US National Academy of Sciences, has called for an end to gifts to doctors by drug companies.
According to the New York Times report, doctors routinely accept money, gifts and free drug samplesfrom pharmaceutical and medical device firms as part of marketing efforts.
From the report:
“It is time for medical schools to end a number of long-accepted relationships and practices that create conflicts of interest, threaten the integrity of their missions and their reputations, and put public trust in jeopardy”.
The School received an "F" grade from the American Medical Students Association for its monitoring and control of drug industry money. Yale scored a "C", University of Pennsylvania an "A" and Stanford a "B".
From the New York Times report:
"David Tian, 24, a first-year Harvard Medical student, said: “Before coming here, I had no idea how much influence companies had on medical education. And it’s something that’s purposely meant to be under the table, providing information under the guise of education when that information is also presented for marketing purposes.”
...
no one disputes that many individual Harvard Medical faculty members receive tens or even hundreds of thousands of dollars a year through industry consulting and speaking fees. Under the school’s disclosure rules, about 1,600 of 8,900 professors and lecturers have reported to the dean that they or a family member had a financial interest in a business related to their teaching, research or clinical care. The reports show 149 with financial ties to Pfizer and 130 with Merck."
The APEsphere troop
The CSR Industry’s Lost Cause
What does the 2009 CRO 100 Best Corporate Citizens list say about the current state of the CSR industry? Perhaps it’s time for a makeover. >>
- 2
- on 12 May 2009
News by Impact
- NIH consults on medical research conflicts rules
- Institute of Medicine condemns gifts to doctors
- Med students react to Big Pharma's influence on courses
- Institute of Medicine condemns gifts to doctors
- Med students react to Big Pharma's influence on courses
- Harvard teaching hospitals cap outside pay
- The compliance department - now with added independence
- Finally, a move towards an independent compliance team
- Uni Researchers Get $33K/Yr from Medical Industry
- Harvard teaching hospitals cap outside pay
- Tough new rules could hit Big Four services fees
- Medical Editors Push for Crackdown on Ghostwriting
- The compliance department - now with added independence
- NIH consults on medical research conflicts rules
- Medical Editors Push for Crackdown on Ghostwriting
- Australia Gives ASIC New Powers to Supervise Markets
- PwC: Were Satyam's auditors independent or entwined?
Andrew Newton 
